Home > Journals > Minerva Obstetrics and Gynecology > Past Issues > Articles online first > Minerva Obstetrics and Gynecology 2021 Nov 26



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Obstetrics and Gynecology 2021 Nov 26

DOI: 10.23736/S2724-606X.21.04964-2


language: English

The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an Italian multicentre prospective observational study

Stefano LELLO 1, 2, Anna CAPOZZI 1, 2 , Anjeza XHOLLI 3, Angelo CAGNACCI 3, 4, on behalf of the Italian Society of Menopause (SIM) and Italian Society of Gynecology of the Third Age of Women (SIGiTE), and of Writing Group of the Pollen Extract in Menopause Italian Study Group

1 Istituto Dermopatico dell’Immacolata-IRCCS, Rome, Italy; 2 Dipartimento Salute Donna e Bambino, Fondazione Policlinico Gemelli-IRCCS, Roma, Italy; 3 Clinica Ostetrica e Ginecologica, IRCCS-Ospedale San Martino, Genova, Italy; 4 Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, IRCCS-Ospedale San Martino, Genova, Italy

BACKGROUND: Purified Cytoplasm of Pollen (PCP) is a non-hormonal herbal remedy used to manage vasomotor symptoms (VMS), sleep and mood disorders in menopausal women not relying on Hormone Replacement Therapy (HRT). Many studies demonstrated its efficacy and safety in post-menopause but few data are available about peri-menopause.
METHODS: This is a multicentre prospective observational study on Italian symptomatic women in peri- and post-menopause referring to gynaecology clinics of different areas of Italy, evaluating the effects of PCP therapy on hot flashes (HFs) and other parameters included in the Greene Climacteric Scale (GCS).
RESULTS: We recruited 108 peri- and post-menopausal women (mean age 53.8 ± 4 yrs), evaluating them at baseline (V0) and after 3 months of PCP treatment (V1). Basal median value of all items of GCS did not differ among all subjects. We found a significant improvement of HFs (p< 0.0001) and night sweats (p< 0.0001) between V0 and V1. Additionally, all items of GCS apart from loss of sensitivity to limbs (p=0.0746) significantly ameliorated after PCP therapy (p< 0.05).
CONCLUSIONS: According to these findings, PCP may be considered as an efficacious alternative non-hormonal treatment for the management of VMS as well as mood and sleep disturbances in both peri- and post-menopause.

KEY WORDS: Purified Cytoplasm of Pollen; Menopause; Perimenopause; Hot flashes; Mood disorders; Sleep disorders; Quality of life

top of page